Showing 2921-2930 of 3185 results for "".
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. V
- Valeant Pharmaceuticals Announces Appointment of Dr. Ari Kellen to Executive Management Teamhttps://practicaldermatology.com/news/20131125-valeant_pharmaceuticals_announces_appointment_of_dr_ari_kellen_to_executive_management_team/2459405/Valeant Pharmaceuticals International, Inc. announced that Dr. Ari Kellen has been named to Valeant's Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1,
- Lithera Announces Appointment of Dr. Lincoln Krochmal as Chief Medical Officerhttps://practicaldermatology.com/news/20131121-lithera_announces_appointment_of_dr_lincoln_krochmal_as_chief_medical_officer/2459407/Lincoln Krochmal, MD was recently appointed as Chief Medical Officer of Lithera, Inc. According to the company, this appointment reflects the company's continued growth as it prepares to enter la
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- Actelion Launches Valchlor to Treat Stage IA and IB Mycosis Fungoides-type Cutaneous T-cell Lymphomahttps://practicaldermatology.com/news/20131119-actelion_launches_valchlor_to_treat_stage_ia_and_ib_mycosis_fungoides-type_cutaneous_t-cell_lymphoma/2459409/The FDA approved Actelion's Valchlor (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine. Valchlor, a gel that is applied topically once a day, is an alkylating drug indicated to treat p
- Clear Clinic Acne Treatment Center Launches New Line, Online Componenthttps://practicaldermatology.com/news/20131119-clear_clinic_acne_treatment_center_launches_new_line_online_component/2459410/Clear Clinic Acne Treatment is launching a line of customized acne products along with an online program. Clear Clinic Online combines customized regimens from a new line of 19 acne products with guided care from a Personal Acne Coach, who will conduct consultations via video e-chat or telephone. Cl
- KLOX Technologies Announces European CE Mark Approval for Non-Invasive Acne Vulgaris Producthttps://practicaldermatology.com/news/20131119-klox_technologies_announces_european_ce_mark_approval_for_non-invasive_acne_vulgaris_product/2459411/KLOX Technologies Inc. announced that it has received CE mark approval in Europe for its topical photo-converter gel as a Class IIa Medical Device for the treatment of acne vulgaris, including all severities. The gel is part of the company's LumiCleanse System, a first-in-class,
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/20131016-asds_elects_new_officers_board_members/2459435/The American Society for Dermatologic Surgery (ASDS) announces the election of Naomi Lawrence, M.D., as Vice President as well as a new Secretary and three new board members during its Annual Meeting in Chicago. The Society's newly elected officials will join President Mitchel P. Goldman, M.D., and
- Humira Found Effective for Hidradentis Suppurativahttps://practicaldermatology.com/news/20131011-humira_found_effective_for_hidradentis_suppurativa/2459436/Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-P
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primarily